All Oncology News

The FDA has granted orphan drug designation to NXC-201 for use as a potential therapeutic option in patients with multiple myeloma.

Japan’s Ministry of Health, Labour, and Welfare has approved fam-trastuzumab deruxtecan-nxki for use in adult patients with unresectable advanced or recurrent, HER2-mutant non–small cell lung cancer that has progressed following chemotherapy.

Fox Chase Cancer Center is pleased to announce the hiring of Christopher G. Cann, MD, as an assistant professor in the Department of Hematology/Oncology with a focus on gastrointestinal cancers.

The FDA has accepted and granted priority review to a supplemental new drug application seeking the approval of enzalutamide in patients with nonmetastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.

The addition of the investigational anti-TIGIT immunotherapy tiragolumab to atezolizumab demonstrated a numerical but not statistically significant improvement in overall survival vs atezolizumab alone as frontline therapy for patients with PD-L1–high, locally advanced or metastatic non–small cell lung cancer.

Michael Cecchini, MD, expands on key updates in gastrointestinal cancer from the 2023 ASCO Annual Meeting, including the clinical significance of findings from the PROSPECT and phase 3 PRODIGE 23 trials of perioperative chemotherapy vs selective standard chemoradiation.

A neoadjuvant treatment regimen consisting of HER2-directed conventional dendritic cell intratumoral therapy plus paclitaxel, trastuzumab, and pertuzumab elicited pathologic complete responses in patients with stage I to III HER2-positive breast cancer.

The European Commission has approved single-agent nivolumab for use in the adjuvant treatment of adult and adolescent patients aged 12 years or older who have stage IIB or IIC melanoma and who have undergone complete resection.

HER2 amplification appears to be prognostic in patients with RAS wild-type metastatic colorectal cancer but may not be predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.

Barbara Pistilli, MD, discusses the mechanism of action of novel ADCs, the ways in which ADC targets in breast cancer can change over time, and how future research may pave the way for individualized treatment with this class of agents.

The Barbara Ann Karmanos Cancer Institute, part of Grand Blanc-based McLaren Health Care and a National Cancer Institute-designated Comprehensive Cancer Center, in conjunction with Wayne State University, have named Boris C. Pasche, MD, PhD, FACP, President & Chief Executive Officer and Chair of the Department of Oncology at the Wayne State University School of Medicine.

Second-line treatment with GNOS-PV02 plus plasmid-encoded interleukin-12 followed by electroporation elicited complete molecular response detected via circulating tumor DNA in 4 additional patients with advanced hepatocellular carcinoma enrolled in the phase 1b/2a GT-30 study.

Selpercatinib demonstrated a statistically significant improvement in progression-free survival vs physician’s choice of cabozantinib or vandetanib in patients with advanced or metastatic RET-mutant medullary thyroid cancer, meeting the primary end point of the phase 3 LIBRETTO-531 trial.

The European Commission has granted conditional marketing authorization to talquetamab-tgvs monotherapy for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 3 prior therapies and have demonstrated disease progression on the last therapy.

Oncologists globally explore trends, challenges in diagnosis, and future directions in patients with colorectal cancer.

Shilpa Gupta, MD, expands on the updated results from EV-103 in patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin, and details the next steps for investigating the combination of enfortumab vedotin plus pembrolizumab in the ongoing phase 3 EV-302 trial.

The novel HER2-targeted bispecific antibody zanidatamab in combination with docetaxel demonstrated efficacy with a manageable safety profile as first-line treatment in patients with advanced HER2-positive breast cancer.

Monica D. Mead, MD, discusses the evolving use of the BTK inhibitors in the treatment of patients with MCL, the factors for selecting between ibrutinib, zanubrutinib, and acalabrutinib, and unmet needs for patients with MCL.

A groundbreaking discovery by Markus Bredel, MD, PhD, and colleagues not only marks a significant milestone in our understanding of diffuse gliomas but also paves the way for improved predictions of disease outcomes and the development of targeted treatment approaches.

The FDA has accepted a new drug application seeking the approval of imetelstat for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndrome.

The FDA has placed another partial clinical hold on the enrollment of new patients in United States clinical trials evaluating the potential first-in-class investigational anti-CD47 immunotherapy magrolimab for the treatment of acute myeloid leukemia.

The FDA has granted an orphan drug designation to the IgG1k type murine monoclonal antibody MAb-AR20.5 for the treatment of patients with pancreatic cancer.

Detection of circulating tumor cells, which are released from primary or metastatic lesions into the bloodstream and are the “seeds” for distant metastatic lesions, has been of interest in cancer research and treatment because these cells can potentially provide information on cancer detection, prognosis, and likelihood of treatment response with minimally invasive methods.

The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer and measurable soft tissue disease following 1 prior novel hormonal therapy, meeting one of the primary end points in the primary analysis of the phase 3 CONTACT-02 trial.

Marios Giannakis, MD, PhD, discusses how targeting the WNT signaling pathway could harness a previously underutilized pathway involved in GI tumor development, spotlights the activity and safety of CGX1321 with or without pembrolizumab in phase 1 studies, and emphasizes the need for continued investigation of CGX1321 to further validate this precision medicine approach.

Furmonertinib had efficacy and an acceptable toxicity profile when utilized as adjuvant treatment in EGFR-mutated, stage IA2-IIIA non–small cell lung cancer with high-risk pathological factors who have undergone radical surgery

TNB-486 demonstrated sustained antitumor activity in all but 1 patient with relapsed/refractory follicular lymphoma, regardless of CD20 status, as well as number and type of prior therapy.

Patients with mismatch repair–deficient and/or microsatellite instability metastatic colorectal cancer experienced a progression-free survival benefit with longer disease control following treatment with avelumab compared with standard second-line chemotherapy.

Second-line treatment with axicabtagene ciloleucel led to an investigator-assessed, 3-month complete metabolic response rate of 71.0% in patients with large B-cell lymphoma who were ineligible for autologous stem cell transplant.

Ajai Chari, MD, discusses how the FDA approval of talquetamab addresses several unmet needs in relapsed/refractory multiple myeloma and expands on the agent’s efficacy data and safety profile observed in MonumenTAL-1.